-
Assessing the Impact of PD-L1 and BRAF Biomarkers on Long-Term Survivorship (LTS) Rates Among Treatment-Naive Advanced Melanoma Patients Receiving Immune Checkpoint Inhibitors (ICIs)
Mar 10, 2025, 14:00 PM -
The Role of Real-World Evidence in Addressing Gaps in Health Technology Assessment in Brazil’s Public Healthcare System
Mar 10, 2025, 14:00 PM -
Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population
Mar 10, 2025, 14:00 PM -
Framework for Real-World Data Used in Regulatory Submissions
Mar 10, 2025, 14:00 PM -
Exploring the Link Between Self-Efficacy and Medication Adherence: Psychometric Evaluation of the Traditional Chinese Beliefs About Medicines Questionnaire-Specific in Adults With Type 2 Diabetes
Mar 10, 2025, 14:00 PM -
A Key Opinion Leader Survey of Major Depressive Disorder (MDD) with Anhedonia in Canada on Frequency, Management, and Burden of MDD With Prominent Anhedonia
Mar 10, 2025, 14:00 PM -
Market Access as Defined by Professionals with Market Access Backgrounds - Scoping Review
Mar 10, 2025, 14:00 PM -
Revisiting Conflicts in Population-Adjusted Indirect Comparisons: A Duality Perspective
Mar 10, 2025, 14:00 PM -
A Framework for Evaluating the Economic and Operational Impact of Adopting the Sentimag®platform for Lesion Localization and Sentinel Lymph Node Biopsy in Women with Breast Cancer
Mar 10, 2025, 14:00 PM -
Large Language Model and Contextual Prioritization of Titles and Abstracts for Systematic Review Screening
Mar 10, 2025, 14:00 PM -
A Contemporary Analysis of Utilization, Clinical Outcomes and Costs of Robotic-Assisted, Laparoscopic, and Open Partial Nephrectomy Using the National Inpatient Sample
Mar 10, 2025, 14:00 PM -
An Overview of Pricing and Reimbursement Frameworks for Medicinal Products in Central and Eastern European (CEE) Countries: Mechanisms, Rules, And Managed Entry Agreements (MEAs)
Mar 10, 2025, 14:00 PM -
US Stakeholder Perspectives on Accumulators, Maximizers, and Alternative Funding Programs: Implications for Patient Affordability and Outcomes Research
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Gabapentin, Pregabalin, and Duloxetine in the Treatment of Painful Diabetic Neuropathy: A Real-World Data-Based Net Benefit Regression Analysis
Mar 10, 2025, 14:00 PM -
Pharmacometric-Pharmacoeconomic Modeling and Simulation to Assess Target Product Profile Characteristics in Early Drug Development: Application to Atopic Dermatitis
Mar 10, 2025, 14:00 PM -
Outcomes of Outpatient Administration of Ciltacabtagene Autoleucel (Cilta-Cel) in Relapsed Refractory Multiple Myeloma (RRMM)
Mar 10, 2025, 14:00 PM -
Potential Added Clinical Value of Polygenic Risk Scores in Risk Assessment of Atherosclerotic Cardiovascular Disease
Mar 10, 2025, 14:00 PM -
Data Extraction from Full-Text PDFs Using Large Language Models for Systematic Reviews
Mar 10, 2025, 14:00 PM -
Canada’s Evolving Market for Biosimilars and What It Means for Payers
Mar 10, 2025, 14:00 PM -
Characterization of Economic Burden in Individuals With Narcolepsy or Idiopathic Hypersomnia at Higher Risk of Sodium-Associated Negative Clinical Outcomes in the United States
Mar 10, 2025, 14:00 PM
